See the published version of this preprint at Arthritis Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Karin Schölin Bywall
Uppsala Universitet Medicinska och farmaceutiska vetenskapsomradet
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5865-5590
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Preference assessments of patients with rheumatoid arthritis (RA) help inform clinical therapeutic decisions for including biologic and targeted synthetic drugs to use. This study assesses patient preferences for biologics or Janus kinases (JAK) inhibitors and heterogeneity within these preferences to estimate the relative importance of treatment characteristics and to calculate the minimum benefit levels patients require to accept higher levels of side effects.
Methods: Between November 2018 to August 2019, patients were recruited to participate in a survey containing demographic and disease-related questions as well as a Discrete Choice Experiment to measure their preferences for second-line therapies using biologics or JAK inhibitors. Treatment characteristics (attributes) included in the DCE were mode of administration, frequency of use, probability of mild short-term side effects, probability of side effects affecting appearance, probability of psychological side effects, probability of severe side effects, and effectiveness of treatment.
Results: A total of 358 patients were included in the analysis. Latent class analysis revealed three preference patterns. When choosing treatment, the respondents found either effectiveness of treatment (34%), mode of administration (28%), or probability of severe side effects as most important (38%). In addition, disease duration and mild side effects influenced the patients’ choices.
Conclusion: Respondents found either effectiveness, severe side effects, or mode of administration as the most important attribute. Patients noting effectiveness as most important were more willing than other patients to accept higher risks of side effects.
Keywords
Discrete choice experiment, Patient preferences, Rheumatoid arthritis, Second-line treatment
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Arthritis Research & Therapy.
No community comments so far
Editorial decision: Accept
On 07 Dec, 2020
Review #1 received
Received 06 Dec, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 25 Nov, 2020
Reviewers invited
Invitations sent on 25 Nov, 2020
Submission checks complete
On 25 Nov, 2020
Editor invited
On 25 Nov, 2020
Version 2
Posted 28 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 15 Nov, 2020
Review #1 received
Received 18 Oct, 2020
Reviewer #1 agreed
On 12 Oct, 2020
Reviewers invited
Invitations sent on 28 Sep, 2020
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Revise before peer review
On 22 Jul, 2020
Editor assigned
On 21 Jul, 2020
First submitted
On 20 Jul, 2020
Submission checks complete
On 20 Jul, 2020
Editor invited
On 20 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Ethics
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Arthritis Research & Therapy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Karin Schölin Bywall
Uppsala Universitet Medicinska och farmaceutiska vetenskapsomradet
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5865-5590
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Arthritis Research & Therapy.
No community comments so far
Editorial decision: Accept
On 07 Dec, 2020
Review #1 received
Received 06 Dec, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 25 Nov, 2020
Reviewers invited
Invitations sent on 25 Nov, 2020
Submission checks complete
On 25 Nov, 2020
Editor invited
On 25 Nov, 2020
Version 2
Posted 28 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 15 Nov, 2020
Review #1 received
Received 18 Oct, 2020
Reviewer #1 agreed
On 12 Oct, 2020
Reviewers invited
Invitations sent on 28 Sep, 2020
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Revise before peer review
On 22 Jul, 2020
Editor assigned
On 21 Jul, 2020
First submitted
On 20 Jul, 2020
Submission checks complete
On 20 Jul, 2020
Editor invited
On 20 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Ethics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Arthritis Research & Therapy.
Background: Preference assessments of patients with rheumatoid arthritis (RA) help inform clinical therapeutic decisions for including biologic and targeted synthetic drugs to use. This study assesses patient preferences for biologics or Janus kinases (JAK) inhibitors and heterogeneity within these preferences to estimate the relative importance of treatment characteristics and to calculate the minimum benefit levels patients require to accept higher levels of side effects.
Methods: Between November 2018 to August 2019, patients were recruited to participate in a survey containing demographic and disease-related questions as well as a Discrete Choice Experiment to measure their preferences for second-line therapies using biologics or JAK inhibitors. Treatment characteristics (attributes) included in the DCE were mode of administration, frequency of use, probability of mild short-term side effects, probability of side effects affecting appearance, probability of psychological side effects, probability of severe side effects, and effectiveness of treatment.
Results: A total of 358 patients were included in the analysis. Latent class analysis revealed three preference patterns. When choosing treatment, the respondents found either effectiveness of treatment (34%), mode of administration (28%), or probability of severe side effects as most important (38%). In addition, disease duration and mild side effects influenced the patients’ choices.
Conclusion: Respondents found either effectiveness, severe side effects, or mode of administration as the most important attribute. Patients noting effectiveness as most important were more willing than other patients to accept higher risks of side effects.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...